

Enrico Orciuolo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9699866/publications.pdf>

Version: 2024-02-01

86
papers

1,490
citations

430874

18
h-index

330143

37
g-index

87
all docs

87
docs citations

87
times ranked

2863
citing authors

#	ARTICLE	IF	CITATIONS
1	Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy. <i>Journal of Hematology and Oncology</i> , 2018, 11, 84.	17.0	241
2	<i>Aspergillus fumigatus</i> suppresses the human cellular immune response via gliotoxin-mediated apoptosis of monocytes. <i>Blood</i> , 2005, 105, 2258-2265.	1.4	183
3	Unexpected cardiotoxicity in haematological bortezomib treated patients. <i>British Journal of Haematology</i> , 2007, 138, 396-397.	2.5	181
4	Radioimmunotherapy with Radretumab in Patients with Relapsed Hematologic Malignancies. <i>Journal of Nuclear Medicine</i> , 2012, 53, 922-927.	5.0	65
5	Effects of <i>Aspergillus fumigatus</i> gliotoxin and methylprednisolone on human neutrophils: implications for the pathogenesis of invasive aspergillosis. <i>Journal of Leukocyte Biology</i> , 2007, 82, 839-848.	3.3	61
6	Cell death and impairment of glucose-stimulated insulin secretion induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in the β -cell line INS-1E. <i>Toxicology and Applied Pharmacology</i> , 2007, 220, 333-340.	2.8	55
7	Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin's lymphoma patients. <i>Annals of Hematology</i> , 2012, 91, 1013-1022.	1.8	36
8	High-dose zinc oral supplementation after stem cell transplantation causes an increase of TRECs and CD4 ⁺ na ⁺ ve lymphocytes and prevents TTV reactivation. <i>Leukemia Research</i> , 2018, 70, 20-24.	0.8	36
9	Human autologous plasma-derived clot as a biological scaffold for mesenchymal stem cells in treatment of orthopedic healing. <i>Journal of Orthopaedic Research</i> , 2008, 26, 176-183.	2.3	34
10	Tumor dormancy as an alternative step in the development of chemoresistance and metastasis - clinical implications. <i>Cellular Oncology (Dordrecht)</i> , 2020, 43, 155-176.	4.4	34
11	Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors: A Registry-Based Study of the Italian Blood and Marrow Transplantation Society (GITMO). <i>Biology of Blood and Marrow Transplantation</i> . 2019, 25, 2388-2397.	2.0	33
12	Safety and efficacy of ⁹⁰ Y-tritium ¹²⁵ I-britumomab ¹²⁵ T-ixetan for untreated follicular lymphoma patients. An Italian cooperative study. <i>British Journal of Haematology</i> , 2014, 164, 710-716.	2.5	31
13	MDR1 diplotypes as prognostic markers in multiple myeloma. <i>Pharmacogenetics and Genomics</i> , 2008, 18, 383-389.	1.5	30
14	Risk of multiple myeloma is associated with polymorphisms within telomerase genes and telomere length. <i>International Journal of Cancer</i> , 2015, 136, E351-8.	5.1	30
15	2CdA chemotherapy and rituximab in the treatment of marginal zone lymphoma. <i>Leukemia Research</i> , 2010, 34, 184-189.	0.8	28
16	CD45 expression in low-grade B-cell non-Hodgkin's lymphomas. <i>Leukemia Research</i> , 2008, 32, 263-267.	0.8	24
17	Lenograstim reduces the incidence of febrile episodes, when compared with filgrastim, in multiple myeloma patients undergoing stem cell mobilization. <i>Leukemia Research</i> , 2011, 35, 899-903.	0.8	20
18	Digital Droplet PCR is a Specific and Sensitive Tool for Detecting IDH2 Mutations in Acute Myeloid Leukemia Patients. <i>Cancers</i> , 2020, 12, 1738.	3.7	20

#	ARTICLE	IF	CITATIONS
19	Impact of polymorphic variation at 7p15.3, 3p22.1 and 2p23.3 loci on risk of multiple myeloma. <i>British Journal of Haematology</i> , 2012, 158, 805-809.	2.5	19
20	A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1814-1822.	2.0	18
21	Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine-based high-dose chemotherapy regimen. <i>British Journal of Haematology</i> , 2016, 172, 111-121.	2.5	16
22	A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: Results from the IMMEnSE consortium and meta-analysis. <i>Oncotarget</i> , 2016, 7, 59029-59048.	1.8	16
23	Lack of association of NQO1 and GSTP1 polymorphisms with multiple myeloma risk. <i>Leukemia Research</i> , 2008, 32, 988-990.	0.8	15
24	Genetics and molecular epidemiology of multiple myeloma: The rationale for the IMMEnSE consortium (Review). <i>International Journal of Oncology</i> , 2011, 40, 625-38.	3.3	14
25	Clinical significance of occult central nervous system disease in adult acute lymphoblastic leukemia. A multicenter report from the Campus ALL Network. <i>Haematologica</i> , 2020, 106, 39-45.	3.5	14
26	Could age modify the effect of genetic variants in IL6 and TNF- α genes in multiple myeloma?. <i>Leukemia Research</i> , 2012, 36, 594-597.	0.8	13
27	Comprehensive investigation of genetic variation in the 8q24 region and multiple myeloma risk in the IMMEnSE consortium. <i>British Journal of Haematology</i> , 2012, 157, 331-338.	2.5	13
28	Genetic Variants and Multiple Myeloma Risk: IMMEnSE Validation of the Best Reported Associations—An Extensive Replication of the Associations from the Candidate Gene Era. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 670-674.	2.5	13
29	Fludarabine, Bortezomib, Myocet [®] and rituximab chemotherapy in relapsed and refractory mantle cell lymphoma. <i>British Journal of Haematology</i> , 2010, 148, 810-812.	2.5	12
30	Type 2 diabetes-related variants influence the risk of developing multiple myeloma: results from the IMMEnSE consortium. <i>Endocrine-Related Cancer</i> , 2015, 22, 545-559.	3.1	11
31	VDTPACEAs Salvage Therapy For Heavily Pretreated MM Patients. <i>Blood</i> , 2013, 122, 5377-5377.	1.4	11
32	MDR1 C3435T Polymorphism Indicates a Different Outcome in Advanced Multiple Myeloma. <i>Acta Haematologica</i> , 2009, 122, 42-45.	1.4	10
33	Genetically determined telomere length and multiple myeloma risk and outcome. <i>Blood Cancer Journal</i> , 2021, 11, 74.	6.2	10
34	PEG-Filgrastim activity on granulocyte functions. <i>Leukemia Research</i> , 2007, 31, 1453-1455.	0.8	9
35	Poor prognosis chronic myeloid leukemia with a complex variant Philadelphia translocation, t(9;10;22)(q34;q24;q11). <i>Leukemia Research</i> , 2007, 31, 1765-1766.	0.8	9
36	Reduction of immunoglobulin levels during imatinib therapy of chronic myeloid leukemia. <i>Leukemia Research</i> , 2008, 32, 191-192.	0.8	9

#	ARTICLE	IF	CITATIONS
37	Two Cases of Plasma Cell Leukemia with Atypical Immunophenotype. <i>Acta Haematologica</i> , 2007, 118, 27-29.	1.4	7
38	Unusual association of endometrial cancer and multiple myeloma. <i>Gynecologic Oncology</i> , 2008, 110, 265-266.	1.4	7
39	Bortezomib with Thalidomide plus Dexamethasone Compared with Thalidomide plus Doxorubicin and Dexamethasone as Induction Therapy in Previously Untreated Multiple Myeloma Patients. <i>Acta Haematologica</i> , 2013, 129, 35-39.	1.4	7
40	Chronic myeloid leukaemia and hairy cell leukaemia coexisting in a single patient: Difficulties at diagnosis and rational of the therapeutic strategy. <i>Leukemia Research</i> , 2006, 30, 349-353.	0.8	6
41	Acute myeloid leukaemia after treatment with ⁹⁰ Y- β ritumomab tiuxetan for follicular lymphoma. <i>Hematological Oncology</i> , 2008, 26, 179-181.	1.7	6
42	Complex translocation t(6;9;22)(p21.1;q34;q11) at diagnosis is a therapy resistance index in chronic myeloid leukaemia. <i>Leukemia Research</i> , 2008, 32, 190-191.	0.8	6
43	Early Diagnosis of Neutropenic Enterocolitis by Bedside Ultrasound in Hematological Malignancies: A Prospective Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 4277.	2.4	6
44	Bortezomib inhibits T-cell function versus infective antigenic stimuli in a dose-dependent manner in vitro. <i>Leukemia Research</i> , 2007, 31, 1026-1027.	0.8	5
45	Transitory marrow aplasia during Imatinib therapy in a patient with chronic myeloid leukemia. <i>Leukemia Research</i> , 2008, 32, 194-195.	0.8	5
46	A polygenic risk score for multiple myeloma risk prediction. <i>European Journal of Human Genetics</i> , 2022, 30, 474-479.	2.8	5
47	Bone and bone marrow interactions: hematological activity of osteoblastic growth peptide (OGP)-derived carboxy-terminal pentapeptide. <i>Leukemia Research</i> , 2004, 28, 1097-1105.	0.8	4
48	MDR1 modulates apoptosis in CD34+ leukemic cells. <i>Annals of Hematology</i> , 2008, 87, 1017-1018.	1.8	4
49	Complex translocation t(3;9;22)(q21;q34;q11) at diagnosis is a negative prognostic index in chronic myeloid leukemia. <i>Leukemia Research</i> , 2008, 32, 192-194.	0.8	4
50	correspondence: CD23 expression in plasma cell leukaemia. <i>British Journal of Haematology</i> , 2010, 150, 724-725.	2.5	4
51	Real-Life Experience With First-Line Therapy Bortezomib Plus Melphalan and Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma Ineligible for High Dose Chemotherapy With Autologous Stem-Cell Transplantation. <i>Frontiers in Medicine</i> , 2021, 8, 712070.	2.6	4
52	The Role of Imaging in Relapse Detection During Follow up: a Fifteen-Year Single Center Experience.. <i>Blood</i> , 2009, 114, 5007-5007.	1.4	4
53	Pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients. <i>Annals of Hematology</i> , 2011, 90, 1115-1116.	1.8	3
54	Sorafenib As Monotherapy or in Association With Cytarabine and Clofarabine for the Treatment of Relapsed/Refractory FLT3 ITD-Positive Advanced Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, e13-e17.	0.4	3

#	ARTICLE	IF	CITATIONS
55	The assessment of minimal residual disease versus that of somatic mutations for predicting the outcome of acute myeloid leukemia patients. <i>Cancer Cell International</i> , 2019, 19, 83.	4.1	3
56	Different types of amyloid concomitantly present in the same patients. <i>Hematology Reports</i> , 2019, 11, 7996.	0.8	3
57	MDR1 pump: More than a drug transporter. <i>Leukemia Research</i> , 2008, 32, 359-360.	0.8	2
58	Bortezomib and Liposomal Doxorubicin Are Highly Effective in Obtaining the Best Possible Response before Autologous Transplant for Multiple Myeloma. <i>Acta Haematologica</i> , 2009, 122, 39-41.	1.4	2
59	PRDI-BF1 and PRDI-BF1 ² isoform expressions correlate with disease status in multiple myeloma patients. <i>Hematology Reports</i> , 2017, 9, 7201.	0.8	2
60	Real-Life Experience with Pomalidomide plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma: A Retrospective and Prospective Study. <i>Medicina (Lithuania)</i> , 2021, 57, 900.	2.0	2
61	Phase II Study of the Combination of Interleukin-2 with Zoledronic Acid As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma. <i>Blood</i> , 2016, 128, 5697-5697.	1.4	2
62	Match unrelated bone marrow transplantation in a case of high risk myelodysplastic syndrome treated with azacitidine and concomitant 1 α ,25-dihydroxyvitamin D ₃ , as differentiating agent. <i>Leukemia Research</i> , 2007, 31, 1321-1323.	0.8	1
63	A therapy resistant myelodysplastic syndrome characterized by the presence of the rare reciprocal translocation t(3;12)(q26.2;p13). <i>Leukemia Research</i> , 2007, 31, 1599-1600.	0.8	1
64	Association of PIM gene translocation and TEL/AML1 rearrangement. <i>Leukemia Research</i> , 2007, 31, 1761-1762.	0.8	1
65	Concomitant appearance of trisomy 8 and isochromosome 17q in a Philadelphia-positive clone in a patient with chronic myeloid leukemia in chronic phase: an alarm for changing therapeutic strategy. <i>Cancer Genetics and Cytogenetics</i> , 2007, 177, 166-167.	1.0	1
66	Stable low IgG levels in relapsed non-Hodgkin's lymphomas. <i>Annals of Hematology</i> , 2007, 86, 851-853.	1.8	1
67	Concomitant translocation t(14;22)(q32;q11) in a case of chronic myeloid leukemia. <i>Leukemia Research</i> , 2008, 32, 188-190.	0.8	1
68	Plasma Cell Disorders and Dialysis-Dependent Renal Failure: Safety and Efficacy of Autologous Stem Cell Transplantation. <i>Acta Haematologica</i> , 2018, 139, 101-103.	1.4	1
69	Role of Yttrium-90 Ibritumomab Tiuxetan (Zevalin®) in Inducing and Maintaining Complete Molecular Response in B Non Hodgkin's Lymphoma Patients in Clinical Complete Remission after Chemotherapy Regimen. <i>Blood</i> , 2007, 110, 4498-4498.	1.4	1
70	TNF- α Polymorphism Modulates the Outcome of Multiple Myeloma Patients Treated with Bortezomib. <i>Blood</i> , 2008, 112, 216-216.	1.4	1
71	Joint Pain and Arthritis as First Clinical Manifestation of Systemic Amyloidosis and Multiple Myeloma: Case Report and Brief Literature Review. <i>Hematology Reports</i> , 2022, 14, 19-23.	0.8	1
72	Other mechanisms to explain the role of reduced folate carrier in cancer. <i>European Journal of Haematology</i> , 2008, 80, 365-365.	2.2	0

#	ARTICLE	IF	CITATIONS
73	Folic acid fortification and cancer risk. <i>Lancet, The</i> , 2008, 371, 1336.	13.7	0
74	The Onset of Monoclonal and Oligoclonal Gammopathies Is a Good Prognostic Factor after Allogeneic Stem Cell Transplantation. <i>Acta Haematologica</i> , 2019, 141, 7-11.	1.4	0
75	Comparison of Bone Marrow Biopsy, Flow Cytometry and PCR Assays To Detect Bone Marrow Involvement in B-Cell Non-Hodgkin Lymphomas.. <i>Blood</i> , 2005, 106, 4670-4670.	1.4	0
76	Pharmacogenetic Study on Multiple Myeloma Patients Treated with DAV Regimen and Autologous Stem Cell Transplantation.. <i>Blood</i> , 2007, 110, 3468-3468.	1.4	0
77	Incidence of Febrile Episode During Stem Cell Mobilization (SCM) After High Dose Cyclophosphamide Chemotherapy (HD-CTX) and G-CSF (filgrastim or lenograstim) Administration in Multiple Myeloma (MM) Patients: II Interim Evaluation. <i>Blood</i> , 2008, 112, 4135-4135.	1.4	0
78	Optimizing Follow up Schedule for Non Hodgkin Lymphoma' Patients by Multi-Objective Analysis.. <i>Blood</i> , 2009, 114, 3945-3945.	1.4	0
79	Age-Dependent Influence of TNF- α Polymorphism on Progression Free Survival of ASCT In Multiple Myeloma Patients. <i>Blood</i> , 2010, 116, 1829-1829.	1.4	0
80	Safety and Efficacy of Pegylated Liposomal Doxorubicin In Combination with Dexamethasone and Bortezomib (VMD) or Lenalidomide (RMD) In Multiple Myeloma Refractory/Relapsed Patients. <i>Blood</i> , 2010, 116, 5033-5033.	1.4	0
81	Polymorphisms in Regulators of Xenobiotic Transport and Metabolism Genes NR1I2 and NR1I3 and Multiple Myeloma Risk: A Case-Control Study in the Context of IMMEnSE Consortium. <i>Blood</i> , 2011, 118, 5014-5014.	1.4	0
82	R-CHOP21 Vs R-CHOP14 in Diffuse Large B-Cell Lymphoma Patients: Results From a Multicentre Retrospective Study. <i>Blood</i> , 2011, 118, 1626-1626.	1.4	0
83	R-CHOP21 Vs R-CHOP14 in 950 Diffuse Large B-Cell Lymphoma Patients: Results of a Multicentre Retrospective Study Form Italian Lymphoma Foundation (FIL). <i>Blood</i> , 2012, 120, 1615-1615.	1.4	0
84	Molecular Remission After VTD or TAD As Induction for Multiple Myeloma: Results with Two Different Methods of Analysis.. <i>Blood</i> , 2012, 120, 2929-2929.	1.4	0
85	CD69 Expression Predicts Favorable Outcome in Multiple Myeloma Patients Treated with VTD. <i>Blood</i> , 2015, 126, 1768-1768.	1.4	0
86	Zinc Oral Supplementation Induces a Significant Rise of TRECs and T CD4+ Naïve and Prevents the Increase of Ttv Viral Load after Stem Cell Transplantation: The Zenith Study. <i>Blood</i> , 2016, 128, 1230-1230.	1.4	0